Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER 3: Oral Semaglutide vs Sitagliptin in T2D
NCT02607865Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02607865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607865.